VivoSeq
0

Pipeline Programs

2

Active Trials

2

Companies Involved

Sex is an early-stage landscape with 0 programs across 2 companies. The most active players are Sprout Pharmaceuticals, Inc, Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

15/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

13

clinical trials

Completed7 · 54%
Unknown status2 · 15%
Terminated2 · 15%
Not yet recruiting1 · 8%
Active, not recruiting1 · 8%

Trial Activity

13 trials

Hypoactive Sexual Desire Disorder in Males
Terminated··Phase 2·NCT04002661·8 enrolled
Dopamine, Reward Learning and Sex Hormones
Unknown status·UUniversity Hospital Tuebingen·N/A·NCT06365515·90 enrolled
Use of Transexamic Acid in Hip Replacement
Unknown status·SSamsung Medical Center·Phase 3·NCT02587845·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)